Literature DB >> 20147647

Serotype and genotype replacement among macrolide-resistant invasive Pneumococci in adults: mechanisms of resistance and association with different transposons.

Laura Calatayud1, Carmen Ardanuy, Fe Tubau, Dora Rolo, Immaculada Grau, Román Pallarés, Rogelio Martín, Josefina Liñares.   

Abstract

The aim of this study was to analyze trends in adult invasive pneumococcal disease (IPD) due to macrolide-resistant strains and to study the evolution of serotypes, genotypes, and macrolide-resistant determinants of strains collected in a prospective study between 1999 and 2007 in Barcelona, Spain. IPD due to macrolide-resistant strains of serotypes included in the 7-valent conjugate vaccine (PCV7) decreased from 2.16/100,000 (pre-PCV7 period, 1999 to 2001) to 0.80/100,000 (late-PCV7 period, 2005 to 2007) (P = 0.001), whereas IPD due to macrolide-resistant strains of non-PCV7 serotypes increased from 1.08/100,000 to 2.83/100,000 (P < 0.001). These changes were related to a fall of clones of PCV7 serotypes (ST81 [P < 0.05], ST90, ST315, and ST17) and an increase in new clones of serotypes 19A and 24F (ST230) and 33F (ST717) in the late-PCV7 period. The most common phenotype was MLS(B) (90.9%), related to the erm(B) gene. The frequent association between MLS(B) phenotype and tetracycline resistance [tet(M) gene], was related to transposons of the Tn916-family such as Tn6002 or Tn3872. In conclusion, overall adult IPD rates due to macrolide-resistant pneumococci stabilized between 1999 and 2007 in Barcelona. The decrease in macrolide-resistant PCV7 pneumococci was balanced by the increase in macrolide-resistant non-PCV7 pneumococci.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20147647      PMCID: PMC2849543          DOI: 10.1128/JCM.01868-09

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  30 in total

1.  Serotype 19f multiresistant pneumococcal clone harboring two erythromycin resistance determinants (erm(B) and mef(A)) in South Africa.

Authors:  L McGee; K P Klugman; A Wasas; T Capper; A Brink
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

2.  Resistance to macrolides and related antibiotics in Streptococcus pneumoniae.

Authors:  Roland Leclercq; Patrice Courvalin
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

3.  Phenotypes and genotypes of erythromycin-resistant pneumococci in Italy.

Authors:  Maria Pia Montanari; Marina Mingoia; Ileana Cochetti; Pietro Emanuele Varaldo
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

4.  Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain (1979-1990).

Authors:  J Liñares; R Pallares; T Alonso; J L Perez; J Ayats; F Gudiol; P F Viladrich; R Martin
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

Review 5.  Evolution of Streptococcus pneumoniae serotypes and antibiotic resistance in Spain: update (1990 to 1996).

Authors:  A Fenoll; I Jado; D Vicioso; A Pérez; J Casal
Journal:  J Clin Microbiol       Date:  1998-12       Impact factor: 5.948

Review 6.  Pneumococcal resistance to antibiotics.

Authors:  K P Klugman
Journal:  Clin Microbiol Rev       Date:  1990-04       Impact factor: 26.132

7.  Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.

Authors:  Cynthia G Whitney; Monica M Farley; James Hadler; Lee H Harrison; Nancy M Bennett; Ruth Lynfield; Arthur Reingold; Paul R Cieslak; Tamara Pilishvili; Delois Jackson; Richard R Facklam; James H Jorgensen; Anne Schuchat
Journal:  N Engl J Med       Date:  2003-05-01       Impact factor: 91.245

8.  A multilocus sequence typing scheme for Streptococcus pneumoniae: identification of clones associated with serious invasive disease.

Authors:  Mark C Enright; Brian G Spratt
Journal:  Microbiology (Reading)       Date:  1998-11       Impact factor: 2.777

9.  Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system.

Authors:  J Sutcliffe; A Tait-Kamradt; L Wondrack
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

10.  Molecular epidemiology of paediatric invasive pneumococcal disease in southern Spain after the introduction of heptavalent pneumococcal conjugate vaccine.

Authors:  I Obando; L A Arroyo; D Sánchez-Tatay; D Tarragó; D Moreno; W P Hausdorff; A B Brueggemann
Journal:  Clin Microbiol Infect       Date:  2007-03       Impact factor: 8.067

View more
  19 in total

1.  Genetic diversity of Tn916-related transposons among drug-resistant Streptococcus pneumoniae isolates colonizing healthy children in Venezuela.

Authors:  Beatríz Quintero; María Araque; Christa van der Gaast-de Jongh; Peter W M Hermans
Journal:  Antimicrob Agents Chemother       Date:  2011-07-25       Impact factor: 5.191

2.  Phenotypes and genotypes of macrolide-resistant streptococcus pneumoniae.

Authors:  Leyla Sirekbasan; Nevriye Gönüllü; Serhat Sirekbasan; Mert Kuşkucu; Kenan Midilli
Journal:  Balkan Med J       Date:  2015-01-01       Impact factor: 2.021

3.  Pneumococci can persistently colonize adult patients with chronic respiratory disease.

Authors:  A Domenech; C Ardanuy; L Balsalobre; S Marti; L Calatayud; A G De la Campa; A B Brueggemann; J Liñares
Journal:  J Clin Microbiol       Date:  2012-10-10       Impact factor: 5.948

4.  Molecular resistance mechanisms of macrolide-resistant invasive Streptococcus pneumoniae isolates from Alaska, 1986 to 2010.

Authors:  Karen Rudolph; Lisa Bulkow; Michael Bruce; Tammy Zulz; Alisa Reasonover; Marcella Harker-Jones; Debby Hurlburt; Thomas Hennessy
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

5.  In vitro activity of ceftobiprole and seven other antimicrobial agents against invasive Streptococcus pneumoniae isolates in Spain.

Authors:  E Ríos Dueñas; I Rodríguez-Avial; J J Picazo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-07-26       Impact factor: 3.267

6.  Population Genomics Reveals Distinct Temporal Association with the Emergence of ST1 Serotype V Group B Streptococcus and Macrolide Resistance in North America.

Authors:  M Belén Cubria; Luis Alberto Vega; William C Shropshire; Misu A Sanson; Brittany J Shah; Shrijana Regmi; Marcia Rench; Carol J Baker; Anthony R Flores
Journal:  Antimicrob Agents Chemother       Date:  2021-10-11       Impact factor: 5.938

7.  Streptococcus pneumoniae Serotypes 9 and 14 Circulating in Brazil over a 23-Year Period Prior to Introduction of the 10-Valent Pneumococcal Conjugate Vaccine: Role of International Clones in the Evolution of Antimicrobial Resistance and Description of a Novel Genotype.

Authors:  Tatiana C A Pinto; Fabíola C O Kegele; Cícero A G Dias; Rosana R Barros; José M Peralta; Vânia L C Merquior; Maria da Gloria Carvalho; Sopio Chochua; Paulina Hawkins; Lesley McGee; Lucia M Teixeira
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

8.  Dominance of multidrug resistant CC271 clones in macrolide-resistant streptococcus pneumoniae in Arizona.

Authors:  Jolene R Bowers; Elizabeth M Driebe; Jennifer L Nibecker; Bette R Wojack; Derek S Sarovich; Ada H Wong; Pius M Brzoska; Nathaniel Hubert; Andrew Knadler; Lindsey M Watson; David M Wagner; Manohar R Furtado; Michael Saubolle; David M Engelthaler; Paul S Keim
Journal:  BMC Microbiol       Date:  2012-01-18       Impact factor: 3.605

9.  Clonal expansion of the macrolide resistant ST386 within pneumococcal serotype 6C in France.

Authors:  Claire Janoir; Robert Cohen; Corinne Levy; Edouard Bingen; Agnès Lepoutre; Laurent Gutmann; Emmanuelle Varon
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

10.  Epidemiology of invasive pneumococcal disease in older people in Spain (2007-2009): implications for future vaccination strategies.

Authors:  Carmen Ardanuy; José María Marimón; Laura Calatayud; Montserrat Giménez; Marta Alonso; Immaculada Grau; Román Pallarés; Emilio Pérez-Trallero; Josefina Liñares
Journal:  PLoS One       Date:  2012-08-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.